1. Department of Pharmacy, People��s Hospital, Peking University, Beijing 100044, China; 2. Department of Pharmacy, People��s Hospital, Henan Province, Zhengzhou 450003, China; 3. Department of Paediatrics, People��s Hospital, Peking University, Beijing 100044, China
Abstract��OBJECTIVE To systematically review the bone metabolism in the epileptic patients receiving oxcarbazepine monotherapy. METHODS Literatures were searched from Pubmed, EMbase, Cochrane Library, CNKI, VIP, Wanfang and CBM database. The included studies were all cohort studies. The quality of studies was evaluated according to the Newcastle-Ottawa Quality Scale (NOS scale). Meta-analysis was performed by the Cochrane Collaboration��s software RevMan5.3. RESULTS Eleven cohort studies were included, all of which were high quality researches (7-8 according to NOS scale). Compared with the control group, serum calcium and 25-OH-VitD declined in the OXC group (P<0.05). In less than half a year of therapy, the 25-OH-VitD level in the OXC group was lower than the control group (P<0.05), but no statistical difference for the serum calcium (P>0.05). In more than half a year of therapy, the serum calcium level in the OXC group was lower than the control group (P<0.05), but no statistical difference for the 25-OH-VitD (P>0.05). For children in the OXC group, both the serum calcium and 25-OH-VitD were decreased (P<0.05) while there was no statistical difference for adults (P>0.05). Besides, all of the serum phosphorus, parathyroid hormone, osteocalcin were not statistically different between the OXC and control groups (P>0.05). In more than half a year of therapy, parathyroid hormone rose above the control group (P<0.05), while both the therapy duration and age of the therapy subjects had no influence in the remaining indexes. Moreover, there was no statistical difference between the two groups for the bone mineral density in different body parts (P>0.05). CONCLUSION Oxcarbazepine may reduce serum calcium and serum 25-OH-VitD, especially for children. Regardless of age, the serum 25-OH-VitD may decline in less than half a year of therapy, while the serum calcium may decline and parathyroid hormone may increase in more than half a year of therapy. Oxcarbazepine had no significant effect on the serum phosphorus, osteocalcin and bone mineral density. All of the included studies in this article are cohort studies with certain limitations as a result of bias risk.
FARHAT G, YAMOUT B, MIKATI M A, et al. Effect of antiepileptic drugs on bone density in ambulatory patients [J]. Neurology, 2002, 58(9):1348-1353.
[2]
MENON B, HARINARAYAN C V. The effect of antiepileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism-a longitudinal study [J]. Seizure, 2010, 19(3):153-158.
[3]
PACK A M. Treatment of epilepsy to optimize bone health [J]. Curr Treat Options Neurol, 2011, 13(4):346-354.
[4]
ZUO Q H. Nervous System Disease in Children(С����ϵͳ����)[M]. Beijing:People Health Publishing House, 2002:246-252.
[5]
CHEN D C, LIAO E Y, XU L, et al. Guidelines for the clinical application of biochemical markers of bone metabolism [J]. Chin J Osteoporosis Bone Miner Res(�л��������ɺǿ��μ�����־), 2015,8(4):283-292.
[6]
CANSU A, YESIKAYA E, SERDAROGLU A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine [J]. Pediatr Neurol, 2008,39(4):266-271.
[7]
WANG L. Comparison of the effects of oxcarbazepine and carbamazepine on bone metabolism in children with epilepsy [J]. J Med Forum(ҽҩ��̳��־),2010,31(14):124-125.
[8]
JIN C,ZHANG S,PANG B D. Study on the effect of new antiepileptic drugs on bone metabolism in children with epilepsy [J]. Maternal Child Health Care Chin (�й����ױ���), 2014,29(5):718-720.
[9]
JU J. Establishment of reference intervals for bone markers in Chinese children and to investigate the effects of epilepsy and antiepileptic drugs on bone metabolism in pediatric patients [D]. Beijing:Chinese PLA General Hospital Medical School of Chinese pla,2015.
[10]
LUO Z H,YANG B. Effect of oxcarbazepine on bone metabolism in children with epilepsy [J]. Anhui Med Pharm J(����ҽҩ),2016,20(9):1759-1762.
[11]
CETINKAYA Y, KURTULMUS Y S, TUTKAVUL K, et al. The effect of oxcarbazepine on bone metabolism [J]. Acta Neurol Scand, 2009, 120(3):170-175.
[12]
WEI C F. The effects of antiepileptic drugs on bone mineral density and on bone metabolism [D]. Zhengzhou: Zhengzhou University,2010.
[13]
GUO H A. Correlation analysis of epilepsy and antiepileptic drugs on bone mineral density and bone metabolism in patients with epilepsy[D]. Tianjin: Tianjin Medical University,2013.
[14]
BAUER S, HOFBAUER L C, RAUNER M, et al. Early detection of bone metabolism changes under different antiepileptic drugs(ED-BoM-AED)-a prospective multicenter study [J]. Epilepsy Res,2013,106(3):417-422.
[15]
KOO D L, HWANG K J, HAN S W, et al. Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy [J]. Epilepsy Res,2014,108(3):442-447.
[16]
LU J, ZENG Q C, WANG Q, et al. Therapeutic effect of oxcarbazepine and levetiracetam in patients with newly diagnosed epilepsy[J]. Neural Injury Functional Reconstruction (�������빦���ؽ�),2016,11(2):125-127.
[17]
LU Y, XU Q. Bone metabolic markers and their application in pediatrics [J]. Chin J Child Heal Care(�й���ͯ������־),2002,10(3):191-193.
[18]
BROADUS A E. Mineral balance and homeostasis. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed [M]. Philadelphia: Lippincott Williams & Wilkins,1999:74-80.
[19]
MCSHEEHY P M, CHAMBERS Y J. Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption [J]. Endocrinology,1986,119(4):1654-1659.
[20]
HAMED S A. Markers of bone turnover in patients with epilepsy and their relationship to management of bone disease induced by antiepileptic drugs[J]. Expert Rev Clin Pharmacol,2016,9(2):267-286.
[21]
XU L, WU Y Y, LIU J L, et al. Effects of bazedoxifene acetate on biochemical markers of bone metabolism in healthy postmenopausal Chinese women in a double-blind, randomized, placebo-controlled study [J]. Clin Pharm J (�й�ҩѧ��־),2007,42(12):949-952.
[22]
BHARADWAJ S, NAIDU A G, BETAGERI G V, et al. Milk ribonuclease -enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women[J]. Osteoporosis Int,2009,20(9):1603-1611.
2017, Vol. 52 
